NDAORALCAPSULEPriority Review
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
MODEYSO (dordaviprone) by Chimerix is protease activators [moa]. Approved for protease activator [epc]. First approved in 2025.
Drug data last refreshed 20h ago
Mechanism of Action
Protease Activators
Pharmacologic Class:
Protease Activator
Indications (1)
Worked on MODEYSO at Chimerix? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.